logo-loader
viewSareum Holdings PLC

Sareum says early findings from study of new potential cancer immuno-therapy garner interest at leading industry conference

“There was a good level of interest directed at novel immunotherapy mechanisms ... and we look forward to further discussions with interested parties"

Cancer cells
Saruem said in an earlier release that it believes it has developed a “potentially powerful” immunotherapy that will help combat the killer diseases.

Sareum Holdings PLC’s (LON:SAR) latest drug candidate has the potential to fight a number of cancers, according to a poster presentation given on Tuesday in the US by the firm’s chief executive, Dr Tim Mitchell.

He said there was a “good level of interest directed” at the company’s discovery from delegates at the American Association for Cancer Research’s annual gathering.

“The conference is an important international cancer congress showcasing innovative research from academic and pharmaceutical organisations from around the world,” the Sareum CEO added.

The presentation noted that in lab models, SDC-1802, a TYK2/JAK1 inhibitor, significantly reduced tumour growth in cancers of the pancreas, colon, skin and kidney, plus B-cell lymphoma.

The studies showed it induced anti-cancer activity through a new mechanism that stimulates the local immune system to attack rogue cells.

The drug was used on its own and in combination with the best treatment currently on the market for the various cancers studied.

Saruem said in an earlier release that it believes it has developed a “potentially powerful” immunotherapy that will help combat the killer diseases.

“There was a good level of interest directed at novel immunotherapy mechanisms such as TYK2/JAK1 inhibition and we look forward to further discussions with interested parties," said CEO Mitchell.

Quick facts: Sareum Holdings PLC

Price: 0.885 GBX

AIM:SAR
Market: AIM
Market Cap: £28.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

2 days, 18 hours ago

2 min read